The Gut–Brain Axis
The bidirectional communication highway between the gut microbiome and the brain — and why it matters for brain health, treatment response, and precision neuropsychiatry.
A Dynamic Bidirectional Network
The gut–brain axis refers to the complex communication network linking the enteric nervous system of the gastrointestinal tract with the central nervous system. This bidirectional communication occurs through neural, endocrine, immune, and metabolic pathways, allowing the gut microbiome to exert direct influence over brain function, mood regulation, neuroinflammation, and treatment response.
Trillions of microorganisms residing in the gut produce neuroactive metabolites — including short-chain fatty acids, neurotransmitters, and immune modulators — that can cross into the bloodstream and influence the brain's biochemical environment. Disruptions to this ecosystem (gut dysbiosis) have been increasingly linked to neuropsychiatric disorders including depression, anxiety, Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
Key Scientific Concepts
Microbiome–Neurotransmitter Axis
Gut bacteria produce and modulate the availability of serotonin, GABA, dopamine precursors, and other neuroactive compounds that directly impact mood, cognition, and neurological function.
Neuroinflammation & Dysbiosis
Gut dysbiosis increases intestinal permeability, allowing microbial metabolites and inflammatory signals to enter systemic circulation and trigger neuroinflammatory cascades implicated in neurodegenerative and psychiatric disease.
Pharmacomicrobiomics
Individual differences in gut microbiome composition significantly affect drug absorption, metabolism, and bioavailability — explaining variable therapeutic responses across patients receiving identical treatments.
From Microbiome Complexity to Clinical Clarity
NeuroBiome harnesses the scientific advances in gut–brain axis research through high-resolution shotgun metagenomic profiling, translating microbiome complexity into precise, clinically actionable therapeutic insights. Our AI platform transforms raw biological data into personalized intervention strategies that support existing neuropsychiatric care.
Key Scientific Publications
A curated selection of peer-reviewed research underpinning the gut–brain axis science at the foundation of NeuroBiome's approach.
Integrated metabolomic and metagenomic profiling reveals distinct signatures in treatment-naïve multiple sclerosis patients
Using shotgun metagenomic sequencing and multi-biofluid metabolomics (urine, stool, serum, and CSF), this study identifies distinct gut microbiome and metabolomic signatures in treatment-naïve MS patients at diagnosis. Key findings include dysregulation of microbially-produced short-chain fatty acids and their systemic bioavailability, linking neuroinflammation to gut microbiome alterations prior to any pharmacological intervention.
Read Preprint →Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
The largest gut microbiome study in MS to date, examining 576 MS patients and 576 genetically unrelated healthy household controls. The study identifies significantly altered bacterial taxa — including increased Akkermansia muciniphila and decreased Faecalibacterium prausnitzii — along with dysregulated metabolic pathways and differential microbiome responses to disease-modifying treatments, establishing a clear link between gut dysbiosis, MS risk, and treatment response.
Read Paper →Gut-brain nexus: Mapping multimodal links to neurodegeneration at biobank scale
A biobank-scale study integrating endocrine, metabolic, nutritional, and digestive disorder data with polygenic risk scores and plasma biomarkers to map the gut-brain nexus in Alzheimer's and Parkinson's disease. Key findings show that multiple gut-related disorders are associated with increased AD/PD risk prior to diagnosis, and that combining gut-brain axis co-occurring disorders with genetic and proteomic data substantially enhances neurodegenerative risk prediction.
Read Paper →Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
A comprehensive review (221k+ accesses, 734 citations) systematically examining the microbiota–gut–brain axis in neurodegeneration, integrating findings across Alzheimer's, Parkinson's, and other neurodegenerative disorders. The review synthesises how the vast genetic and metabolic potential of the gut microbiome influences brain health across development, aging, and disease, with particular focus on therapeutic strategies.
Read Paper →Why nurturing the gut microbiota could resolve depression and anxiety
An in-depth feature reporting on the growing clinical evidence linking gut microbiota composition to depression and anxiety, and covering early-phase clinical trials of faecal microbiota transplantation (FMT) as a treatment for treatment-resistant depression. The article outlines the promising trajectory toward large-scale trials of probiotic and microbiome-targeted psychiatric interventions.
Read Article →Multi-omics approach identifies gut microbiota variations associated with depression
A multi-omics integration study combining metagenomics, metabolomics, and clinical data to identify specific gut microbiota signatures associated with depression. The study reveals reproducible microbial and metabolic patterns linked to depressive symptoms, supporting microbiome-informed precision approaches for psychiatric intervention.
Read Paper →The effects of oral probiotic intervention on brain structure and function in human adults: a systematic review
A systematic review of 26 articles from 19 randomised, placebo-controlled trials (762 subjects) assessing oral probiotic interventions on brain structure and function using neuroimaging and electrophysiology. Probiotic intake was found to modify resting-state brain connectivity and activity, reduce engagement of brain regions during negative emotional stimulation, and improve sleep quality — providing objective neurobiological evidence for the gut–brain axis.
Read Paper →The neuroactive potential of the human gut microbiota in quality of life and depression
This landmark study demonstrates that specific gut bacteria — particularly Coprococcus and Dialister — are consistently depleted in individuals with depression, independently of antidepressant use. By mapping the neuroactive potential of the human gut microbiome through metagenomics, the authors show that microbial synthesis of GABA precursors and other neuroactive metabolites correlates with quality of life, establishing a direct link between gut microbiome composition and neuropsychiatric health outcomes.
Read Paper → (DOI: 10.1038/s41564-018-0337-x)